| pubmed-article:1269429 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1269429 | lifeskim:mentions | umls-concept:C0341628 | lld:lifeskim |
| pubmed-article:1269429 | lifeskim:mentions | umls-concept:C0003364 | lld:lifeskim |
| pubmed-article:1269429 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:1269429 | pubmed:dateCreated | 1976-8-2 | lld:pubmed |
| pubmed-article:1269429 | pubmed:abstractText | 40 patients with essential hypertension of varying degrees were treated with prazosin for up to 6 months. Both in severe (n=10) and in moderately severe (n=28) hypertension a significant decrease of the systolic and diastolic blood pressure was observed after only one month of treatment. This effect was even more evident after 3 and 6 months. 18 patiets showed orthostatic disorders at the beginning of treatment which in all cases disappeared after several weeks. No side effects were observed which could be attributed with certainty to prazosin. | lld:pubmed |
| pubmed-article:1269429 | pubmed:language | ger | lld:pubmed |
| pubmed-article:1269429 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1269429 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1269429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1269429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1269429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1269429 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1269429 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1269429 | pubmed:issn | 0012-0472 | lld:pubmed |
| pubmed-article:1269429 | pubmed:author | pubmed-author:BolzanoKK | lld:pubmed |
| pubmed-article:1269429 | pubmed:author | pubmed-author:KremplerFF | lld:pubmed |
| pubmed-article:1269429 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1269429 | pubmed:day | 4 | lld:pubmed |
| pubmed-article:1269429 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:1269429 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1269429 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1269429 | pubmed:pagination | 882-5 | lld:pubmed |
| pubmed-article:1269429 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:meshHeading | pubmed-meshheading:1269429-... | lld:pubmed |
| pubmed-article:1269429 | pubmed:year | 1976 | lld:pubmed |
| pubmed-article:1269429 | pubmed:articleTitle | [Prazosin--a new antihypertensive agent (author's transl)]. | lld:pubmed |
| pubmed-article:1269429 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1269429 | pubmed:publicationType | English Abstract | lld:pubmed |
